Calliditas hits $90m jackpot as biotech IPO craze continuesSwedish biotech Calliditas has raised $90 million in an upsized US IPO and private placement, valuing the rare kidney and liver disease Share XCalliditas hits $90m jackpot as biotech IPO craze continueshttps://pharmaphorum.com/news/calliditas-hits-90m-jackpot-as-biotech-ipo-craze-continues/
European regulators grant fast path to market for Calliditas’ rare kidney disease drugEuropean regulators have granted a fast path to market for Calliditas Therapeutics’ potential rare kidney disease drug, Nefecon, Share XEuropean regulators grant fast path to market for Calliditas’ rare kidney disease drughttps://pharmaphorum.com/news/european-grant-fast-path-to-market-for-calliditas-rare-kidney-disease-drug/
FDA agrees to downsized trial for Calliditas’ rare disease drugThe FDA has just made it easier for Sweden’s Calliditas to develop Nefecon for a rare kidney disease, Share XFDA agrees to downsized trial for Calliditas’ rare disease drughttps://pharmaphorum.com/news/fda-agrees-to-downsized-trial-for-calliditas-rare-disease-drug/
